Discovery and pharmacological characterization of a new class of prolyl-tRNA synthetase inhibitor for anti-fibrosis therapy

Scleroderma has clinical characteristics including skin and other tissue fibrosis, but there is an unmet need for anti-fibrotic therapy. Halofuginone (HF) is a well-known anti-fibrosis agent in preclinical and clinical studies which exerts its effect via inhibition of TGF-β/Smad3 signaling pathway....

Descripción completa

Detalles Bibliográficos
Autores principales: Shibata, Akira, Kuno, Masako, Adachi, Ryutaro, Sato, Yosuke, Hattori, Harumi, Matsuda, Atsushi, Okuzono, Yuumi, Igaki, Keiko, Tominari, Yusuke, Takagi, Terufumi, Yabuki, Masato, Okaniwa, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655428/
https://www.ncbi.nlm.nih.gov/pubmed/29065190
http://dx.doi.org/10.1371/journal.pone.0186587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655428/
https://www.ncbi.nlm.nih.gov/pubmed/29065190
http://dx.doi.org/10.1371/journal.pone.0186587

Ejemplares similares